Key facts
as of Sep 2026- It has raised $308.0M; the latest was Grant ($10.0M) in Jan 2025.
- Notable investors include Qiming Venture Partners, Morningside Group, Sands Capital, Samsara BioCapital, Illumina Ventures — 10 tracked in total.
- 2 institutional filers report fund marks on Alamar Biosciences across 2 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Alamar Biosciences
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Alamar Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
2 filers · latest Apr 20262 SEC-registered funds reported 2 fair-value marks on Alamar Biosciences between Apr 2026 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Alamar Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alamar Biosciences
Developer of a precision proteomics platform designed for protein analysis and the detection of cancer. The company's platform focuses on creating antibody technologies for the diagnosis of diseases like cancer and empowering new biomarker discoveries for early detection and prevention of common diseases, enabling healthcare providers to detect and possibly cure patients at an early stage.
- Sector
- Healthcare
- HQ
- Fremont, CA, United States
- Founded
- 2018
- Employees
- 177
- Website
- alamarbio.com/
- Ownership
- Privately Held (backing)